Ruminococcus Bromii Test · Stool

Most fiber in your diet never gets digested by your own enzymes. It reaches your colon intact, and what happens next depends heavily on which microbes are living there. One bacterium, Ruminococcus bromii, plays an outsized role in that handoff. It is the primary degrader of resistant starch, the type of fiber found in cooked and cooled potatoes, green bananas, oats, and legumes.

Knowing your level of this organism gives you a window into how well your gut is set up to extract value from fiber. Low levels have been linked to chronic kidney disease, chronic pancreatitis, infant eczema, and poor response to certain immune therapies. Higher levels have tracked with better colon cancer survival and lower inflammation in ulcerative colitis.

What This Bacterium Actually Does

R. bromii (Ruminococcus bromii) is what microbiologists call a keystone species. It can unlock resistant starch that almost no other gut microbe can access. When it breaks that starch down, it releases sugars and produces a short-chain fatty acid called acetate. Other beneficial bacteria, particularly butyrate producers like Faecalibacterium prausnitzii and Eubacterium rectale, then feed on those leftovers and produce butyrate, the fuel source that keeps your colon lining healthy.

This cross-feeding matters because butyrate is one of the most important molecules your gut makes. It powers the cells lining your colon, helps regulate your immune system, and appears to influence inflammation throughout your body. Without R. bromii kicking off the process, the whole chain slows down.

Diet Shapes This Bacterium More Than Almost Any Other Factor

When people eat more resistant starch, R. bromii abundance can climb from a few percent of gut bacteria to roughly 10 to 20 percent of the total. That shift is specific. Other types of fiber, like inulin or wheat bran, produce much smaller changes or none at all. The relationship is also reversible. When the starch intake drops, so does the bacterium, sometimes within days.

Individual responses vary considerably. Some people show dramatic increases in R. bromii on a high resistant starch diet, while others show almost none. This is one of the reasons a baseline test and follow-up testing matter more than a single reading.

Colon Cancer Prognosis

In a study of 348 colon cancer patients, a microbiome signature driven by R. bromii was associated with better survival outcomes. Researchers combined the bacterium's abundance with an immune marker to build a prognostic score that identified patients with excellent survival probability. This does not mean the bacterium causes better outcomes, but it sits inside a biological pattern that tracks with them.

Chronic Kidney Disease

In a study of 88 people, R. bromii abundance decreased as chronic kidney disease progressed. A model that combined R. bromii with specific metabolites was able to stratify disease severity and outperformed serum creatinine for identifying mild kidney disease. Low levels associated with worse kidney function and faster fibrosis progression.

Infant Skin and Immune Development

In a study of 66 infants, those with higher R. bromii at one year of age had more fecal butyrate and a lower risk of developing atopic dermatitis. The association held even after accounting for major butyrate-producing species, suggesting R. bromii contributes to early immune development through its own cross-feeding role.

Chronic Pancreatitis and Diabetes

In a study of 40 people, R. bromii abundance dropped progressively from healthy controls to chronic pancreatitis patients to those with chronic pancreatitis plus diabetes. The reduction tracked with markers of barrier disruption and metabolic dysfunction.

Inflammatory Bowel Disease

In a 28-person randomized trial of people with quiescent ulcerative colitis, a Mediterranean diet pattern increased R. bromii along with short-chain fatty acids and reduced markers of intestinal inflammation. Higher R. bromii is also part of a butyrate-producer-rich profile linked to better response to fecal microbiota transplantation in UC (ulcerative colitis).

When Higher Is Not Always Better

R. bromii does not fit a clean 'higher is better' framework. In a 42-person study of people with muscle-invasive bladder cancer on a type of immune therapy called pembrolizumab, higher stool R. bromii was more common in those who did not respond to the drug. In gestational diabetes, R. bromii was found to be higher, not lower, and correlated positively with body weight and glucose. And in type 2 diabetes, the drug berberine worked partly by inhibiting R. bromii and altering bile acid metabolism, which then lowered blood sugar.

This is not a contradiction. R. bromii is a phenotype indicator, not a simple good or bad marker. Its abundance reflects how your gut processes starch and bile acids, and whether that processing helps or hurts depends on context: the disease you have, the drugs you take, and the rest of your microbial community. The same species can be protective in one setting and unhelpful in another. That is why the number on its own does not tell you what to do. It tells you what pattern your gut is in, which then has to be interpreted alongside everything else.

Reference Ranges

R. bromii is a research-stage microbiome marker. No clinical guideline body has established standardized cutpoints, and different labs use different sequencing methods (16S rRNA, shotgun metagenomics, and PCR-based assays) that can produce different numbers on the same sample. The ranges below reflect patterns reported across dietary and disease studies. They are illustrative orientation, not clinical targets. Your lab will likely report different numbers, and the most meaningful comparisons are within your own results over time.

Source: Abell et al. 2008, Walker et al. 2011, Wang et al. 2023, Jandhyala et al. 2017. Compare your results within the same lab over time for the most meaningful trend.

Why One Reading Is Not Enough

Gut microbiome composition shifts with diet, medications, travel, and illness. R. bromii specifically can rise or fall within days based on how much resistant starch you eat. A single stool sample captures a snapshot, not a trend. If you are trying to see whether your diet is shifting your gut in a useful direction, or whether an intervention is working, you need at least a baseline and a follow-up.

A reasonable approach: test now for a baseline, retest in 3 to 6 months if you are making significant dietary or medication changes, and then at least annually thereafter. If you add a high resistant starch food to your routine, a retest 8 to 12 weeks later can tell you whether your gut is responding. Formal intra-individual variability has not been characterized for R. bromii, which is another reason a single number should not drive decisions.

When Results Can Be Misleading

Several common situations can distort a single R. bromii reading:

• Recent dietary changes: your intake of resistant starch in the days before collection can meaningfully shift abundance. A weekend of eating green bananas or cold potato salad could raise the number; a stretch of mostly protein and refined carbs could lower it.
• Recent antibiotics: any recent course of antibiotics can suppress many gut species including R. bromii. Wait at least several weeks, and ideally longer, before testing.
• Proton pump inhibitors (PPIs): drugs like omeprazole and pantoprazole reduce the broader bacterial family R. bromii belongs to (Ruminococcaceae) and lower overall gut diversity. This is a measurement confounder, not a sign of underlying disease.
• Berberine and related compounds: the plant compound berberine has been shown to specifically suppress R. bromii. If you are taking it for blood sugar or cholesterol, expect a lower number.

What to Do With an Abnormal Result

If your R. bromii is low, the first question to ask is whether your diet is supplying enough resistant starch to feed it. If it is, and the level still does not climb with a dedicated dietary change over 8 to 12 weeks, that is useful information about your gut's responsiveness and may warrant looking at the rest of the microbiome profile, including overall diversity and butyrate-producing species. A full stool microbiome panel gives you more context than R. bromii alone.

Decisions about diagnosis or treatment of gut disease should never rest on this single marker. If you have symptoms that made you curious about R. bromii in the first place, such as chronic digestive issues, a diagnosed inflammatory condition, or metabolic disease, a gastroenterologist can help put the number in context alongside symptoms, standard labs, and other microbiome data.